What does it mean when a standard echocardiogram shows normal left ventricular wall motion and normal left ventricular systolic function but the global longitudinal strain is –11%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

A GLS of -11% Indicates Severe Left Ventricular Systolic Dysfunction Despite Normal Ejection Fraction

A global longitudinal strain (GLS) of -11% represents severe subclinical left ventricular systolic dysfunction and signals significant myocardial impairment that carries important prognostic implications, even when conventional echocardiography shows normal wall motion and preserved ejection fraction. This discordance between ejection fraction and GLS is clinically significant and requires further investigation to identify the underlying cause.

Understanding the Discordance

The apparent contradiction between "normal" systolic function by visual assessment and severely abnormal GLS reflects a fundamental limitation of ejection fraction as a measure of ventricular function. Ejection fraction can remain preserved through compensatory mechanisms—specifically, maintained circumferential strain and supranormal LV twisting—even when longitudinal function of the subendocardial fibers is severely impaired 1. This is particularly common in:

  • Early stages of restrictive cardiomyopathy
  • Hypertrophic cardiomyopathy
  • Infiltrative cardiomyopathies (cardiac amyloidosis, Loeffler's cardiomyopathy)
  • Heart failure with preserved ejection fraction (HFpEF)

Severity Classification

According to established guidelines, GLS values < -10% are consistent with severe reduction of global longitudinal strain 1. For context:

  • Normal GLS: < -18% (more negative values indicate better function) 2, 3
  • Borderline: -16% to -18% 3
  • Mildly abnormal: < -16% 1
  • Severely abnormal: < -10% 1

Your patient's GLS of -11% falls just above the severe threshold but represents marked dysfunction that is four times more common than reduced ejection fraction in detecting early ventricular impairment 4.

Prognostic Implications

This finding carries significant prognostic weight. Patients with abnormal GLS but normal ejection fraction have a 2.4-fold increased risk of cardiovascular events (stroke, myocardial infarction, vascular death) compared to those with normal GLS 4. The prognostic value of GLS is incremental to traditional risk factors and ejection fraction 4.

Differential Diagnosis to Consider

Infiltrative Cardiomyopathies (High Priority)

Cardiac amyloidosis should be strongly considered, particularly if there are:

  • Bilateral carpal tunnel syndrome
  • Lumbar/cervical spinal stenosis
  • Spontaneous biceps tendon rupture
  • Low voltage-to-mass ratio on ECG (not just low voltage)
  • Thickened interatrial septum or valve leaflets
  • Persistent low-level troponin elevation 5

In infiltrative diseases, regional longitudinal strain shows prominent reduction of basal LV segments while the reduction appears more generalized in HCM 1.

Hypertrophic Cardiomyopathy

Even with "normal" wall motion by visual assessment, HCM patients demonstrate reduced GLS similar to patients with reduced ejection fraction 1. An LVEF of 50-55% in HCM may actually represent early impairment 6.

Heart Failure with Preserved Ejection Fraction

GLS assessment is mandatory in all patients with HF when LVEF is preserved 1. The severely reduced GLS indicates that this patient likely has significant diastolic dysfunction and elevated filling pressures despite preserved ejection fraction.

Cardiotoxicity

If there is any history of chemotherapy (particularly anthracyclines or trastuzumab), a relative reduction in GLS of >15% from baseline or an absolute GLS worse than -16% predicts subsequent cardiotoxicity 7, 8.

Immediate Next Steps

  1. Review the regional strain pattern: Look for apical sparing (suggests amyloidosis) vs. generalized reduction (suggests HCM or other diffuse process) 1

  2. Comprehensive diastolic function assessment: Evaluate E/e' ratio, left atrial size, pulmonary artery pressures, and mitral inflow patterns 1

  3. Obtain cardiac biomarkers: Persistent troponin elevation and elevated natriuretic peptides support underlying cardiomyopathy 5

  4. ECG analysis: Calculate voltage-to-mass ratio (more sensitive than low voltage alone for amyloidosis) 5

  5. Detailed history: Specifically ask about:

    • Orthopedic procedures (shoulder, hip, knee)
    • Carpal tunnel syndrome (may precede cardiac symptoms by 5-10 years)
    • Family history of cardiomyopathy or sudden death
    • Chemotherapy exposure 5, 6
  6. Cardiac MRI with late gadolinium enhancement: Essential for differentiating between cardiomyopathies, assessing for fibrosis, and evaluating extracellular volume expansion 6, 2

  7. Consider nuclear imaging: If amyloidosis is suspected, technetium pyrophosphate scanning can diagnose ATTR cardiac amyloidosis non-invasively 5

Critical Pitfalls to Avoid

  • Do not dismiss this as "normal" based on preserved ejection fraction alone—the severely reduced GLS indicates real pathology with prognostic significance
  • Do not attribute findings to hypertension alone—while hypertension can reduce GLS, values this low typically indicate additional pathology 9
  • Ensure measurement quality: GLS has moderate interobserver variability (r=0.71), so verify the measurement was technically adequate 10
  • Remember vendor variability: While global parameters now have small vendor differences, confirm the reference ranges for your specific equipment 3, 11

Clinical Bottom Line

This patient has severe subclinical left ventricular systolic dysfunction that warrants comprehensive evaluation for underlying cardiomyopathy, particularly infiltrative disease or HCM. The preserved ejection fraction is maintained through compensatory mechanisms that will eventually fail. Early identification and treatment of the underlying cause may prevent progression to overt heart failure and reduce the risk of adverse cardiovascular events.

References

Related Questions

What is the normal range for strain in echocardiography (echo)
Given the echocardiographic measurements (left‑ventricular stroke volume ~50 mL, low stroke‑volume index, ejection fraction ≈48 %, fractional shortening 27 %, global longitudinal strain –9 %, concentric hypertrophy with relative wall thickness ~0.52, E/A ratio 0.43, E/e′ ≈4.4, aortic valve area 1.0 cm², mean gradient 18 mmHg, peak gradient 33 mmHg, TAPSE 2.1 cm), what is the overall interpretation and what guideline‑directed medical therapy and further work‑up should be recommended?
Given the echocardiogram showing left ventricular ejection fraction 48% in the four‑chamber view (63% in the two‑chamber view), global longitudinal strain –10%, average mitral valve E/e′ 13.8, left atrial volume index 28.6 mL/m², tricuspid annular plane systolic excursion 1.5 cm, and mild aortic stenosis (mean gradient 3 mmHg, peak gradient 6 mmHg, valve area 1.31 cm²), what is the appropriate management?
What is the significance of an average global longitudinal strain of -18%?
What does an abnormal left ventricular (LV) strain of -15 indicate and what are its potential causes?
What is the recommended terlipressin dose and dilution regimen for treating hepatorenal syndrome?
Can a patient with pulmonary tuberculosis work overtime?
Does flucloxacillin provide adequate coverage for Clostridium tetani in the treatment of tetanus?
What is the appropriate deep vein thrombosis (DVT) prophylaxis regimen for adult hospitalized patients, including dosing, timing after major orthopedic surgery, renal dose adjustments, and recommendations for pregnant patients?
How should abnormal liver function tests (ALT, AST, bilirubin) be managed in a patient receiving enfortumab vedotin?
What is the treatment success rate of imiquimod (Aldara) for superficial basal cell carcinoma (sBCC) on the nose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.